Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance

NCT06995833 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06995833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06995833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
September 19, 2025
Completion date
June 29, 2029
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer